AstraZeneca And Daiichi Sankyo's Datopotamab Deruxtecan Extended Progression-Free Survival Vs. Chemotherapy In Patients With HR-Positive, HER2-Low Or Negative Breast Cancer In TROPION-Breast01 Phase III Trial
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca and Daiichi Sankyo's drug, datopotamab deruxtecan, has shown positive results in the TROPION-Breast01 Phase III trial, reducing the risk of disease progression or death by 37% in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer. The drug also demonstrated a favorable safety profile over chemotherapy. The companies plan to continue discussions with regulatory authorities to bring the drug to eligible patients as soon as possible.
October 23, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's drug, datopotamab deruxtecan, developed in partnership with Daiichi Sankyo, has shown positive results in a Phase III trial. This could potentially lead to regulatory approval and a new revenue stream for the company.
The positive results from the Phase III trial of datopotamab deruxtecan indicate a high likelihood of regulatory approval. This could lead to a new revenue stream for AstraZeneca, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100